Search results for "compensation"

showing 10 items of 407 documents

Clinical value of increased serum creatinine concentration as predictor of short-term outcome in decompensated cirrhosis

2004

The purpose of this study was to assess whether serum creatinine concentration alone or associated with other biological parameters was an independent predictor of short-term mortality in patients with decompensated cirrhosis.A total of 212 consecutive episodes of decompensated cirrhosis in patients admitted to the hospital between January 1999 and December 2001 were reviewed retrospectively. Depending on a serum creatinine concentration equal to or greater than 1.5 mg/dL at the time of admission, patients were divided into decompensated cirrhosis with renal failure (101 episodes in 59 patients, aged 69.8 +/- 10 years) and without renal failure (111 episodes in 61 patients, aged 64.5 +/- 13…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisGastroenterologyLiver diseasechemistry.chemical_compoundInternal medicinemedicineHumansDecompensationHospital MortalityRenal InsufficiencySurvival rateSerum AlbuminAgedCreatinineModels Statisticalbusiness.industryGastroenterologyBilirubinMiddle AgedPrognosismedicine.diseaseDecompensated cirrhosisSurgerySurvival RateTreatment OutcomeROC CurveEl NiñochemistryCreatinineFemalebusinessBiomarkersKidney diseaseScandinavian Journal of Gastroenterology
researchProduct

Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function

2022

The number of effective systemic therapies for the treatment of advanced hepatocellular carcinoma (HCC) is rapidly increasing, and the advent of immunotherapy has changed the treatment paradigm for these patients, leading to significantly improved survival outcomes. However, many patients with HCC will continue to receive tyrosine kinase inhibitors, partly because of contraindications to immune checkpoint inhibitors. Currently, the best sequential first- and second-line systemic treatment remains elusive. Maintenance of optimal liver function is crucial, it is likely to impinge on temporary or permanent treatment discontinuation, and should also be considered when defining the treatment seq…

Liver CirrhosisTyrosine kinase inhibitorsSettore MED/12 - GastroenterologiaCarcinoma HepatocellularHepatologyDecompensation Free Survival; Hepatocellular carcinoma; Immune checkpoint inhibitor; Overall Survival; Progression Free Survival; Systemic therapies; Time to Decompensation; Time to Progression; Tyrosine kinase inhibitorsSystemic therapieHepatocellular carcinomaOverall SurvivalDecompensation Free SurvivalLiver NeoplasmsGastroenterologyTime to DecompensationTyrosine kinase inhibitorSystemic therapiesImmune checkpoint inhibitorTime to ProgressionProgression Free SurvivalHumansImmunotherapy
researchProduct

Prescription rates of common medications in patients with decompensated cirrhosis in Germany

2021

Adequate pharmacological treatment is of pivotal importance to improve prognosis in patients with decompensated liver cirrhosis. We studied the adherence to recommended pharmacological treatments as secondary prevention in cirrhotic patients following a first decompensation in German primary care.Using the Disease Analyzer Database, the current study sample included patients with liver cirrhosis who had an initial diagnosis of a first decompensation event between 2015 and 2018 (index date) and a follow-up time of at least 6 months after the index date. Pharmacological treatments following the 6 months after the index date were studied.The study included 1538 patients with a first decompensa…

Liver Cirrhosismedicine.medical_specialtyCirrhosisEsophageal and Gastric Variceschemistry.chemical_compoundSpontaneous bacterial peritonitisInternal medicineAscitesmedicineHumansDecompensationMedical prescriptionHepatic encephalopathybusiness.industryGastroenterologyAscitesHepatologymedicine.diseaseRifaximinPrescriptionsPharmaceutical PreparationschemistryHepatic Encephalopathymedicine.symptomGastrointestinal HemorrhagebusinessZeitschrift für Gastroenterologie
researchProduct

Hepatitis C-related cirrhosis. Current status.

2016

Chronic hepatitis C virus (HCV) infection affects around 150 million people. It is a leading cause of liver related morbidity and mortality through its predisposition to liver fibrosis, cirrhosis and end-stage liver complications. New treatments based on direct-acting antivirals have opened a new era in the management of HCV cirrhosis. They allow for HCV eradication without substantial side effects in almost all cirrhotic patients, reducing the risk of hepatocellular carcinoma, liver decompensation and mortality. This review provides an update on HCV cirrhosis. The paper focuses on the disease burden and major progresses in the diagnosis, follow-up and treatment of this patient subgroup.

Liver Cirrhosismedicine.medical_specialtyCirrhosisLiver fibrosisGlobal HealthGastroenterologyAntiviral AgentsVirus03 medical and health sciences0302 clinical medicineChronic hepatitisInternal medicinemedicineHumansLiver decompensationDisease burdenbusiness.industryHepatitis CHepatitis C Chronicmedicine.diseaseCombined Modality Therapydigestive system diseasesLiver TransplantationSpain030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyDrug Therapy CombinationbusinessMedicina clinica
researchProduct

Aminopyrine breath test predicts liver-related events and death in HCV-related cirrhosis on SVR after DAA therapy

2019

Background & Aims: In patients with hepatitis C virus (HCV)-related advanced cirrhosis, the effects of sustained virological response (SVR) by direct antiviral agents (DAAs) on decompensation and liver deaths are less clearcut, since up to 30% of patients do not improve, and no predictors of outcome have been identified. We used 13C-aminopyrine breath test (ABT) to assess whether its changes can predict liver-related outcomes after DAA treatment in patients with HCV cirrhosis. Methods: Fifty consecutive patients with HCV cirrhosis were enrolled. Patients were included if they had Child A cirrhosis at risk for decompensation – defined as Child A6 (N = 22, 44%) or previous decompensation …

Liver Cirrhosismedicine.medical_specialtyCirrhosisSofosbuvirHepatitis C virusHepacivirusmedicine.disease_causeAntiviral AgentsGastroenterologyInternal medicineHumansMedicineDecompensationAminopyrineChildCIRRHOSISHepatic encephalopathyaminopyrine breath testBreath testHepatologymedicine.diagnostic_testdirect antiviral agentCumulative dosebusiness.industryHepatitis C Chronicmedicine.diseaseHepatitis CBreath Testsliver functionLiver functionbusinessDIRECT ANTIVIRAL AGENTSAMINOPYRINE BREATH TEST; CIRRHOSIS; DIRECT ANTIVIRAL AGENTS; LIVER FUNCTIONmedicine.drugcirrhosi
researchProduct

Fibrosis in chronic viral hepatitis

2011

In the last years, several studies have been performed with the aim to evaluate the real impact of antiviral treatments on fibrosis progression in patients with chronic viral hepatitis. The main goal of therapy in patients with chronic hepatitis B is viral suppression. This outcome leads to an important improvement in both hepatic inflammation and fibrosis and reduces the HCC occurrence. An histological improvement has been largely demonstrated in patient treated with oral nucleoside and nucleotide analogs achieving the rate of 72% with entecavir and tenofovir. Similarly, in patients with chronic hepatitis C, sustained virologic response to interferon therapy is associated with regression o…

Liver Cirrhosismedicine.medical_specialtyPathologyInterferon therapyGastroenterologyHepatitis B ChronicFibrosisInternal medicinemedicineHumansIn patientViral suppressionLiver decompensationliver fibrosisbusiness.industryGastroenterologyEntecavirHepatitis C Chronicmedicine.diseaseAnti-Retroviral AgentsVirologic responseReverse Transcriptase InhibitorsInterferonsbusinessViral hepatitismedicine.drug
researchProduct

Compensation. Dépôt de garantie, Créance de restitution, Créance de la compagnie pétrolière non déclarée, Compensation avant le jugement d'ouverture …

1996

International audience; (Com. 17 mai 1994, Brunet-Beaumel ès qual. c/ Cogemco et autre ; CA Versailles 15 sept. 1994, Soc. Locafinancière c/ Soc. Télétechnique et autres)

Location-gérance[SHS.DROIT]Humanities and Social Sciences/Law[SHS.DROIT] Humanities and Social Sciences/LawREDRESSEMENT ET LIQUIDATION JUDICIAIRESCompensation légaleCréanceCompensation
researchProduct

The Impact of CEO Long-Term Equity-Based Compensation Incentives on Economic Growth in Collectivist Versus Individualist Countries

2015

This study examines the impact of the prevalence of long-term equity-based CEO compensation incentives on GDP growth, and we address the moderating role of individualist versus collectivist cultures on this relationship. We argue long-term incentives given to CEOs in some firms may convey to other CEOs that they too may be able to receive such incentives and rewards if they emulate the incentivized and rewarded CEOs. In a longitudinal study across twenty-two nations over a five-year period, we find that when a higher proportion of CEOs in a country are awarded long-term equity-based incentive compensation, the greater future real GDP growth, particularly in collectivist countries.

Longitudinal studyIndividualismLabour economicsExecutive compensationIncentiveComputingMilieux_THECOMPUTINGPROFESSIONReal gross domestic productCompensation (psychology)CollectivismEquity (finance)EconomicsComputingMilieux_MISCELLANEOUSGeneralLiterature_MISCELLANEOUSSSRN Electronic Journal
researchProduct

When kidneys and lungs suffer together

2018

A significant interaction between kidneys and lungs has been shown in physiological and pathological conditions. The two organs can both be targets of the same systemic disease (eg., some vasculitides). Moreover, loss of normal function of either of them can induce direct and indirect dysregulation of the other one. Subjects suffering from COPD may have systemic inflammation, hypoxemia, endothelial dysfunction, increased sympathetic activation and increased aortic stiffness. As well as the exposure to nicotine, all the foresaid factors can induce a microvascular damage, albuminuria, and a worsening of renal function. Renal failure in COPD can be unrecognized since elderly and frail patients…

Lung DiseasesNephrologymedicine.medical_specialty030232 urology & nephrologyRenal functionSettore MED/10 - Malattie Dell'Apparato Respiratorio030204 cardiovascular system & hematologyLung injuryPulmonary Disease Chronic Obstructive03 medical and health sciencesMechanical ventilation0302 clinical medicineRenal DialysisInternal medicineAcute lung injuryCOPD; Pulmonary-renal syndrome; Mechanical ventilation; Acute lung injury; Acute kidney injuryHumansCOPDMedicinebusiness.industryAcute kidney injurymedicine.diseaseAcute kidney injuryrespiratory tract diseasesPneumoniaNephrologyPulmonary-renal syndromeAlbuminuriaCardiologyKidney Failure ChronicKidney Diseasesmedicine.symptomRenal compensationbusinessKidney diseaseJournal of Nephrology
researchProduct

Adaptive predictor control for stabilizing pressure in a managed pressure drilling system under time-delay

2016

Abstract In this paper, we address adaptive predictor feedback design for a simplified ODE drilling system in the presence of unknown parameter, disturbance and time-delay. The main objective is to stabilize the bottomhole pressure at a critical depth at a desired set-point directly. The time-delay in the transmission line of the drilling systems is considered. The stabilization of the dynamic system and the asymptotic tracking are demonstrated by the proposed predictor control, where the adaptation employs Lyapunov update law design with normalization. The proposed method is evaluated using a high fidelity drilling simulator and cases from a North Sea drilling operation are simulated. The …

Lyapunov functionNormalization (statistics)0209 industrial biotechnologyEngineeringAdaptive controlbusiness.industryOde0102 computer and information sciences02 engineering and technologyTracking (particle physics)01 natural sciencesIndustrial and Manufacturing EngineeringComputer Science ApplicationsCompensation (engineering)symbols.namesake020901 industrial engineering & automation010201 computation theory & mathematicsControl and Systems EngineeringTransmission lineControl theoryModeling and SimulationsymbolsbusinessSimulationJournal of Process Control
researchProduct